Matritech's cervical cancer test wins US patent:
This article was originally published in Clinica
Matritech has received a US patent covering its NMP179 protein marker test for cervical cancer. The test is based on the company's Nuclear Matrix Protein (NMP) technology, which correlates levels of NMPs in body fluids to the presence of cancer. It has already shown promising results in recent studies (see Clinica No 840, p 16). The test could improve cancer detection in the early stages when the rate of survival is greater than 90% and also reduce the cost and discomfort associated with traditional Pap smear follow-up procedures such as colposcopy, according to Matritech of Newton, Massachusetts.
You may also be interested in...
Dr Reddy's is poised to expand its OTC offering in Russia and certain CIS countries by snapping up a basket of allergy brands from fellow Indian firm Glenmark.
Sandoz has launched an awareness campaign under the banner of “Ask For Generics” in the US. The initiative is aiming to educate stakeholders on the benefits of generics and their quality, safety and efficacy.
European Commission proposals for strengthening intellectual property protections in the EU, particularly the supplementary protection certificate (SPC) system, have been broadly welcomed by Europe’s brand industry. But the medical NGO, MSF, says the SPC proposals run counter to the commission’s own efforts to improve access to medicines.